Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Olumacostat Glasaretil Gel in acne vulgaris
NCT03127956Phase 3Completed
- Sponsor
- Dermira, Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of olumacostat glasaretil in acne vulgaris, sponsored by Dermira, Inc. Primary endpoint: Long-Term Safety Assessed Through Adverse Events and Local Skin Reactions. Started Mar 2017; status: completed.
02
Drugs
olumacostat glasaretil
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03127956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127956.